Home>>New Products>>GMax™ Liposome2000 Transfection Reagent

GMax™ Liposome2000 Transfection Reagent (Synonyms: Lipo6000)

Catalog No.GK20005

GMax™ Liposome2000 Transfection Reagent is a proprietary formulation for transfecting nucleic acids into a wide range of eukaryotic cells.

Products are for research use only. Not for human use. We do not sell to patients.

GMax™ Liposome2000 Transfection Reagent Chemical Structure

Size Price Stock Qty
0.75mL
$200.00
In stock
1.5mL
$360.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 7 publications

Description Protocol Components Product Documents Related Video Related Products

GMax™ Liposome2000 Transfection Reagent is a proprietary formulation for transfecting nucleic acids into a wide range of eukaryotic cells. DNA-GMax™ Liposome2000 complexes must be made in serum-free medium such as Opti-MEM® Reduced Serum Medium and can be added directly to cells in culture medium, in the presence or absence of serum/antibiotic. It is not necessary to remove complexes or change/add medium after transfection. The amount of GMax™ Liposome2000 Reagent required for successful transfection varies depending on the cell type and passage number. Start any new transfection by testing the recommended four concentrations of GMax™ Liposome2000 Reagent to determine an optimum amount.

Reviews

Review for GMax™ Liposome2000 Transfection Reagent

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GMax™ Liposome2000 Transfection Reagent

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.